Randomized Trialvery high evidence
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
The New England journal of medicine·January 8, 2026·PMID 41211925
Why it mattersThis trial extends the proven benefit of PCSK9 inhibition to a primary prevention population with atherosclerosis or diabetes, a group not previously studied in dedicated outcomes trials. It provides evidence for evolocumab use in patients without prior MI or stroke who remain at elevated cardiovascular risk.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled